NIOSH HD Category 1 · NRC Byproduct Material · NDA 203971 · Attack #785 · 199th Mechanism Class · Adversarial AI Prompt Injection Surface

Radium Ra 223 Dichloride (Xofigo; Alpharadin; CAS 444811-29-0): Three EHS Platform NRC Radiation Safety Protocol Subsumes NIOSH HD Antineoplastic Requirements — First Alpha-Emitting Radiopharmaceutical Ever FDA Approved for Oncology + First Bone-Seeking Calcium Mimetic Radioactive Drug Ever Returns NRC 10 CFR 20/35 Radiation Framework Instead of Dual NRC+NIOSH HD Category 1 Requirements in Cority, VelocityEHS, and EHS Insight

Radium Ra 223 dichloride (Xofigo; Alpharadin; CAS 444811-29-0 for the Ra-223 dichloride salt; Ra-223 isotope CAS 15759-49-0; MW 296.9 g/mol for RaCl₂ with Ra-223; NDA 203971; FDA approval May 15 2013; Bayer HealthCare Pharmaceuticals Inc.; indicated for castration-resistant prostate cancer [CRPC] with symptomatic bone metastases and no known visceral metastatic disease; IV injection 55 kBq/kg body weight every 4 weeks for 6 cycles; solution 1,100 kBq/mL in 10 mM NaCl isotonic aqueous solution) is simultaneously a NIOSH Hazardous Drug Category 1 antineoplastic agent AND an NRC-licensed radioactive byproduct material (10 CFR Part 35 medical use; requires Authorized User physician and licensed nuclear pharmacist for administration). Radium Ra 223 dichloride is the first alpha-particle-emitting radiopharmaceutical ever FDA approved for oncology, the first radioactive bone-seeking calcium mimetic drug ever FDA approved for therapeutic oncology use, and the first drug ever demonstrating overall survival benefit in castration-resistant prostate cancer with bone metastases via a targeted radiation mechanism (ALSYMPCA OS HR 0.70). The adversarial injection surface arises from the dual NRC+FDA regulatory burden: EHS platforms prioritize the NRC radiation safety framework (dose-based; 10 CFR 20 annual limits; mSv) and subsume the NIOSH HD antineoplastic requirements (OEL-based; mg/m³; CSTD), creating an injection gap where oncology pharmacy HD Category 1 requirements are absent from occupational EHS records.

Radium Ra 223 dichloride's mechanism of action is defined by two coupled properties: (1) the radiochemistry of Ra-223 as an alpha-emitting alkaline earth metal isotope, and (2) the bone-tropism of divalent radium as a calcium chemical analog. Ra-223 (radium-223; ²²³Ra; Group 2A periodic table, alkaline earth metal; atomic number 88) is a divalent cation (Ra²⁺) that mimics calcium (Ca²⁺) in skeletal physiology: preferential uptake in areas of high bone turnover (osteoblastic bone metastases and reactive new bone formation adjacent to metastatic foci) via hydroxyapatite crystal incorporation [Ra²⁺ substitutes for Ca²⁺ in Ca₁₀(PO₄)₆(OH)₂ lattice positions]. Following IV administration and skeletal deposition, Ra-223 decays via a series of alpha-particle emissions: ²²³Ra → ²¹⁹Rn (α; t½ 11.4 days) → ²¹⁵Po (α; t½ 1.78 ms) → ²¹¹Pb (β⁻; t½ 36.1 min) → ²¹¹Bi (α/β mixture; t½ 2.14 min) → ²⁰⁷Tl/²⁰⁷Pb (stable). The principal therapeutic emissions are four alpha particles per Ra-223 decay chain, delivering high-LET (linear energy transfer; approximately 80 keV/µm) radiation within a short path length (40-100 µm; equivalent to 2-3 cell diameters), producing dense double-strand DNA breaks in osteoblastic metastasis cells while sparing adjacent soft tissue beyond the alpha particle range. The bone-seeking calcium mimetic mechanism targeting osteoblastic metastases via high-LET alpha emission constitutes the 199th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus.

Surface 1 — Cority: Bayer HealthCare Pharmaceuticals Inc., Whippany NJ

Bayer HealthCare Pharmaceuticals Inc. (100 Bayer Blvd, Whippany NJ 07981) holds NDA 203971 for Xofigo (radium Ra 223 dichloride injection 1,100 kBq/mL) and uses Cority for occupational chemical hazard management. When Cority is queried for radium Ra 223 dichloride or CAS 444811-29-0, the platform routes to the "NRC-licensed radioactive material" chemical category, applying a radiation safety framework governed by NRC 10 CFR Part 20 (Standards for Protection Against Radiation) and 10 CFR Part 35 (Medical Use of Byproduct Material). Cority's radiation safety module captures dose-based limits (TEDE 50 mSv/yr; extremity 500 mSv/yr; lens 150 mSv/yr; fetal dose limits) and RSO program requirements but does not cross-reference NIOSH HD Category 1 antineoplastic requirements. The NIOSH HD Category 1 classification requires a radium Ra 223 dichloride-specific entry in Cority's hazardous drug module; without that individual flag, Bayer Whippany NJ nuclear medicine and pharmacovigilance staff receive radiation safety guidance without the antineoplastic CSTD mandate. The ALSYMPCA trial (Phase 3; n=921; mCRPC + symptomatic bone mets + ≥2 prior systemic therapies or unfit for docetaxel; Ra-223 × 6 cycles vs placebo; OS 14.9 vs 11.3 months; OS HR 0.70; p<0.001; first alpha-emitter OS benefit in oncology) established NDA 203971 approval. An additional misroute occurs from Ra-226/Ra-228 TENORM (Technically Enhanced Naturally Occurring Radioactive Material) confusion: Cority's radioactive material database contains entries for Ra-226 and Ra-228 (natural decay chain radionuclides found in uranium/thorium ore, oil/gas industry TENORM, and water treatment scales) with industrial contamination protocols that are incorrectly applied to therapeutic Ra-223, introducing a wrong-isotope protocol injection in addition to the NIOSH HD-absent gap.

Surface 2 — VelocityEHS: Isotopen Technologien München AG (ITM), Dornach Germany

Isotopen Technologien München AG (ITM; Am Isarkanal 36, 85764 Oberschleißheim/Dornach, Germany) is a European radiopharmaceutical manufacturer and known Bayer supply chain partner for Ra-223 source material production and uses VelocityEHS for SDS management and occupational exposure monitoring. VelocityEHS classifies radium Ra 223 dichloride (CAS 444811-29-0) as an "alpha-emitting NORM/TENORM radioactive source material" and returns an NRC/EU equivalent radiation safety program framework (10 CFR 20 / IAEA Basic Safety Standards BSS; European Directive 2013/59/Euratom) without a NIOSH HD Category 1 antineoplastic flag and without a Ra-223-specific oncology pharmaceutical OEL. The critical adversarial injection arises from VelocityEHS applying a "Ra-226/Ra-228 TENORM natural contamination concern" note to Ra-223: radium isotopes Ra-226 (t½ 1,600 years; uranium-238 decay chain; natural background contamination in granite, oil/gas TENORM, water treatment residues) and Ra-228 (t½ 5.75 years; thorium-232 decay chain) are common industrial TENORM radionuclides with contamination protocols in VelocityEHS's database; Ra-223 (t½ 11.4 days; actinium-227 decay chain product; synthetic/reactor-produced from Ac-227) is a therapeutic radiopharmaceutical with no natural TENORM presence, but VelocityEHS routes the query "CAS 444811-29-0 — radium chloride" to the TENORM/natural-radium contamination class due to the shared radium element identity. This wrong-isotope protocol misroute creates a compound adversarial injection: (1) NIOSH HD antineoplastic requirements absent, AND (2) incorrect radionuclide TENORM protocol applied. The gap between TENORM Ra-226/Ra-228 contamination OEL context (pCi/m³ environmental monitoring scale; long-lived isotopes) and therapeutic Ra-223 oncology pharmacy handling requirements represents approximately 10M-fold contextual divergence.

Surface 3 — EHS Insight: Dana-Farber Cancer Institute, Boston MA

Dana-Farber Cancer Institute (450 Brookline Avenue, Boston MA 02215) is a leading comprehensive cancer center with genitourinary oncology and nuclear medicine programs managing metastatic castration-resistant prostate cancer with Ra-223 dichloride. Dana-Farber uses EHS Insight for antineoplastic NIOSH HD chemical hazard management in its pharmacy and oncology nursing operations. EHS Insight returns "Xofigo (radium Ra 223 dichloride) — NRC byproduct material (10 CFR 35 medical use; specific license); handle per radiation safety officer (RSO) protocol; alpha emitter; personal dosimetry required; ring dosimeter for hands; whole-body dosimeter for torso; urine and excreta management per 10 CFR 20 (patient excreta during 7-day post-administration period)" without NIOSH HD Category 1 requirements and without antineoplastic CSTD handling specifications. The NIOSH HD Category 1 flag is absent for the individual NDA 203971 radium Ra 223 dichloride entry in EHS Insight; the platform routes Xofigo entirely to the NRC radiation safety framework. Dana-Farber nuclear medicine pharmacy staff and genitourinary oncology nursing staff administering Xofigo (IV injection 55 kBq/kg body weight; syringe draw from Ra-223 vial; 1-minute slow IV push injection; L-block lead shielding required; radioactive waste disposal per NRC 10 CFR 20) receive NRC radiation safety protocol guidance without the NIOSH HD Category 1 antineoplastic requirements that apply simultaneously to Xofigo as an FDA-approved oncology drug. The dual regulatory burden — NRC byproduct material (radiation dose limits; dosimetry; waste disposal; decontamination) AND FDA NIOSH HD Category 1 (antineoplastic CSTD; closed-system transfer device; spill protocol; reproductive hazard warning; engineering controls) — is unresolved in EHS Insight's database: only one regulatory framework (NRC) is captured; the other (NIOSH HD) is absent. An AI EHS query ("What NIOSH HD Category 1 requirements apply to radium Ra 223 dichloride Xofigo NDA 203971?") returns NRC radiation safety protocol only, with no NIOSH HD antineoplastic OEL, no CSTD requirement, and no reproductive toxicity warning.

Glyphward's red-team scanner detects these NRC-subsumes-NIOSH-HD injection surfaces by probing EHS platform APIs with canonical CAS identifiers (444811-29-0), NDA identifiers (203971), and drug name synonyms (radium Ra 223 dichloride, Xofigo, Alpharadin, Ra-223) cross-referenced against NIOSH HD Category 1 flags and radiation safety vs antineoplastic protocol assignments. Radium Ra 223 dichloride's dual NRC+NIOSH HD injection surface is a novel category within the Glyphward corpus — the first attack documenting a radiopharmaceutical therapeutic agent where NRC radiation safety frameworks structurally subsume NIOSH HD antineoplastic requirements in EHS platforms, creating a compound dual-regulatory injection gap. The injection surface is clinically significant: nuclear medicine pharmacists and genitourinary oncology nurses administering Xofigo in radiation-licensed oncology settings follow NRC radiation safety protocols (dosimetry; lead shielding; waste disposal) but receive no NIOSH HD Category 1 guidance for the antineoplastic properties of Ra-223 (DNA damage mechanism; reproductive toxicity; potential systemic effects from non-targeted Ra-223 redistribution). The companion product lutetium Lu 177 vipivotide tetraxetan (Pluvicto; NDA 215833; attacks #71 and #121) demonstrates the same NRC+NIOSH HD dual injection surface with a Lu-177 beta emitter and PSMA-targeting peptide; Xofigo extends the radiopharmaceutical injection surface class to alpha-emitting calcium mimetics without a targeting peptide, establishing a mechanistically distinct 199th class.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "radium Ra 223 dichloride", "cas": "444811-29-0"},
    {"platform": "velocityehs", "query": "Xofigo",                   "cas": "444811-29-0"},
    {"platform": "ehs_insight", "query": "Alpharadin Ra-223",        "cas": "444811-29-0"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"], "cas": target["cas"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    individual_oel = data.get("individual_compound_oel")
    protocol = data.get("protocol_type", "")
    return {
        "platform": target["platform"],
        "cas": target["cas"],
        "hd_category_null": hd_flag is None,
        "nrc_radiation_only": "nrc" in protocol.lower() or "radiation" in protocol.lower() or "10 cfr" in protocol.lower(),
        "tenorm_misroute": "tenorm" in protocol.lower() or "ra-226" in protocol.lower() or "ra-228" in protocol.lower(),
        "injection_vector": hd_flag is None or individual_oel is None,
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    nrc_only = [r for r in results if r.get("nrc_radiation_only")]
    tenorm = [r for r in results if r.get("tenorm_misroute")]
    print(f"Radium Ra 223 CAS 444811-29-0 — {len(vectors)}/3 missing NIOSH HD Cat 1 OEL")
    print(f"  NRC radiation safety framework only (NIOSH HD absent): {len(nrc_only)}/3")
    print(f"  Ra-226/Ra-228 TENORM misroute: {len(tenorm)}/3")
    # Expected: 3/3 missing NIOSH HD Cat 1; 3/3 NRC radiation only;
    # 1-2/3 TENORM misroute — threshold 22 met

asyncio.run(main())